site stats

Telara pharma sl

WebMay 11, 2024 · Telara Pharma - Funding, Financials, Valuation & Investors Organization Telara Pharma Summary Financials People Technology Signals & News Similar Companies Highlights Funding Rounds 1 Total Funding Amount €100K Lead Investors 1 Investors 1 Funding Telara Pharma has raised a total of €100K in funding over 1 round. WebArch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation; Novel Mechanism of Action – selective dipeptidase-1 (DPEP-1 ...

GENESIS Biomed has led the closing of a € 100,000 seed round for Telara ...

WebCompany type: Sociedad Limitada, Active: VAT Number (CIF) B02839470: Universal Entity Code: 8351-6250-1732-0076: Record last updated: Thursday, July 21, 2024 8:56:16 PM UTC WebApr 16, 2024 · Arch Biopartners Inc. has announced the signing of a licensing agreement with Telara Pharma SL for its patents relating to Cilastatin, dipeptidase-1 (DPEP-1) antagonists. The licensing deal which awards commercial rights for the patents, is put through mainly for Arch to use them in developing a treatment for acute kidney injury. simplify 1 - 3 https://inkyoriginals.com

Scrip

Web--Arch Biopartners Inc., announced today it has entered into an exclusive worldwide license agreement with Telara Pharma of Spain to clinically develop and market cilastatin, a small-molecule drug ... WebTelara Pharma has designed a drug capable of preventing acute kidney injury. Headquarters Location Madrid, Spain Suggest an edit Missing: Telara Pharma 's … WebTelara Pharma – Developing therapeutic solutions for the prevention and treatment of kidney disease and sepsis. We use cookies on our website to give you the most relevant … Acute kidney Injury (AKI) is a syndrome that results in a sudden decrease in kidney … Cilastatin: a potential treatment strategy against COVID-19 that may decrease … Telara Pharma awarded at the 8th IiSGM Research and Innovation Conference … Telara Pharma S.L. is a spin-off company from the Gregorio Marañón Health … Great! Thank you for you message! We will get back to you real soon. With the creation of Telara Pharma to try to bring cilastatin into clinical use, we … Company (referred to as either “the Company”, “We”, “Us” or “Our” in this … Telara Pharma S.L. has been created in Madrid (Spain), acquiring a license … simplify 132 : 48

Arch Biopartners Enters into Worldwide License Agreement with Telara ...

Category:Genesis Biomed drives Telara Pharma, a spin-off from the …

Tags:Telara pharma sl

Telara pharma sl

TELARA PHARMA SL B02839470 - en.datocapital.es

WebTelara Pharma designs a drug capable in the treatment and prevention of acute kidney injury. Lists Featuring This Company City of Madrid Companies With Fewer Than 100 … WebApr 15, 2024 · Arch Biopartners ( OTCQB:ACHFF) announces that it has entered into an exclusive worldwide license agreement with Telara Pharma of Spain to clinically develop and market cilastatin, a...

Telara pharma sl

Did you know?

WebApr 15, 2024 · Arch Biopartners Inc. announced it has entered into an exclusive worldwide license agreement with Telara Pharma of Spain (“Telara”) to clinically develop and market cilastatin, a small-molecule drug candidate for […] WebMay 10, 2024 · The company's drug is a small molecule inhibitor of the dipeptidase-1 (DPEP-1) enzyme to prevent degradation of the Imipenem antibiotic in the kidney, enabling doctors to prevent the patients from the toxicity of other drugs and generalized infections from causing kidney damage. Contact Information Website www.telarapharma.com …

WebMay 14, 2024 · Business Description Telara Pharma S.L. is a spin-off company from the Gregorio Marañón Health Research Institute (IiSGM), Gregorio Marañón Universitary … WebSee Telara Pharma funding rounds, investors, investments, exits and more. Evaluate their financials based on Telara Pharma's post-money valuation and revenue.

WebMay 14, 2024 · Telara Pharma S.L. is a spin-off company from the Gregorio Marañón Health Research Institute (IiSGM), Gregorio Marañón Universitary General Hospital focused and committed to kidney disease improvement. We are developing a new therapeutic strategy for the treatment of acute kidney injury induced by toxics, sepsis, and sepsis-included … WebSee Telara Pharma funding rounds, investors, investments, exits and more. Evaluate their financials based on Telara Pharma's post-money valuation and revenue.

WebApr 15, 2024 · Telara Pharma is focused on the research, development, and marketing of drugs for the treatment of high prevalence pathologies (mainly kidney injuries and …

WebMay 10, 2024 · The company's drug is a small molecule inhibitor of the dipeptidase-1 (DPEP-1) enzyme to prevent degradation of the Imipenem antibiotic in the kidney, enabling … simplify 132WebMay 10, 2024 · Phoenix project will provide services for the development, characterization, testing, safety assessment, scale-up, good manufacturing practices (GMPs) production … simplify 13 2WebApr 14, 2024 · Clinical Specialist - SL Altamonte Springs, FL, USA * Florida, USA * Store 320, Altamonte Springs, Florida, United States of America Req #28843 … simplify 13 1/5 x 17 1/5WebApr 15, 2024 · Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation Novel Mechanism of Action - simplify 13 + 2 - 5 - 15 -5 -25 5WebMay 11, 2024 · Cilastatin is a small molecule inhibitor of the dipeptidase-1 (DPEP-1) enzyme developed in the 1980s to prevent degradation of the Imipenem antibiotic in the kidney. Until now, the use of cilastatin is limited to the combination in dual formulation with the antibiotic imipenem, and it has not yet been approved as a stand-alone product. raymond plack mdWebUna spin-off para el proyecto Cilastatina, el primer nefroprotector del mundo descubierto por el fallecido Dr. Tejedor y su equipo simplify 1/3 + 2/5 – 2/6WebTelara Pharma S.L. - BioCentury Company Profiles for the biopharma industry simplify 13/25